Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of apixaban to medicine for treating diabetic foot

A technology of apixaban and diabetic foot, which is applied in the application field of apixaban in the treatment of diabetic foot, can solve the problems of unsatisfactory control of diabetic foot disease, achieve stable therapeutic effect, and be convenient to take and absorb Effect

Inactive Publication Date: 2017-06-30
JIANGSU WANBANG BIOPHARMLS +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] On the basis of the above treatments, the disease control of diabetic foot is still not ideal, and it is urgent to develop new auxiliary drugs for further treatment in clinical practice.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of apixaban to medicine for treating diabetic foot

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 The therapeutic effect of apixaban on diabetic foot

[0023] 1. Materials and methods

[0024] 1.1 Experimental objects and grouping

[0025] Randomly selected outpatients and inpatients with type 2 diabetes (all in line with WHO diagnostic criteria) had resting limb pain, intermittent claudication, weakened dorsal artery pulse, cold dorsum of foot or ulcers on toes and heels A total of 25 cases of patients, (including 2 cases of osteomyelitis). Do lower extremity nerve conduction velocity measurements have slowed down. The age of the patients was 60.3±12.4 years old, including 15 males and 10 females.

[0026] 1.2 Treatment methods

[0027] After diet and drug control of blood sugar and infection were stabilized, apixaban was used for treatment, and the changes of hemorheology before and after 1 month of treatment with apixaban were observed.

[0028] The recommended dose of apixaban is 2.5 mg each time, taken orally twice a day with water, regardless of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to novel application of a medicine, and in particular relates to a treatment effect of apixaban on diabetic foot. A clinical trial research provided by the invention proves that the apixaban used as a reversible, direct and high-selectivity Xa factor active site inhibitor which is potent and is orally available can be used for inhibiting free and thrombus-combined Xa factors and inhibiting prothrombinase activity. By inhibiting the Xa factors, the apixaban can be used for inhibiting the generation of thrombin and inhibiting the formation of thrombus; erythrocyte deformability is further improved, the blood and plasma viscosity is reduced, and acra blood circulation is promoted, so that the apixaban has a good treatment effect on the diabetic foot.

Description

technical field [0001] The invention relates to a new application of medicine, in particular to the application of apixaban in medicine for treating diabetic foot. Background technique [0002] Diabetes is one of the major diseases endangering human health, and it is a lifelong metabolic disease characterized by chronic hyperglycemia. Long-term hyperglycemia can lead to damage to large blood vessels and microvessels and endanger the heart, brain, kidney, peripheral nerves, eyes, feet, etc., causing a variety of complications. Quality of life also threatens the patient's illness. [0003] Diabetic foot (DF) is one of the most serious complications of diabetes. Foot problems are one of the common reasons for diabetic patients to be hospitalized. About 50% of elderly patients with type 2 diabetes are risk factors for foot problems. About 15% of diabetic patients will develop disease within 10 years of their lives. Diabetes over 10 years Foot ulcers or gangrene occurred in 66...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4545A61K45/06A61P3/10A61P17/02
CPCA61K9/0053A61K31/4545A61K45/06
Inventor 高雪芹李惠珠王伟乔德水
Owner JIANGSU WANBANG BIOPHARMLS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com